CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Treatment of higher-risk patients with an indication for revascularization: evolution within the field of contemporary percutaneous coronary intervention Major infections after bypass surgery and stenting for multivessel coronary disease in the randomised SYNTAX trial Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Better Prognosis After Complete Revascularization Using Contemporary Coronary Stents in Patients With Chronic Kidney Disease Radionuclide Image-Guided Repair of the Heart ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography

Guideline2014 Jul 1;63(25 Pt B):2889-934.

JOURNAL:J Am Coll Cardiol. Article Link

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Stone NJ, Robinson JG, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Keywords: ACC/AHA Practice Guideline; biomarkers, pharmacological; cardiovascular disease; cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction behavior; secondary prevention

Full Text PDF